Get the Stockscreener App
3.34
7.22%
-0.26
Anixa Biosciences Inc stock is traded at $3.34, with a volume of 168.08K.
It is down -7.22% in the last 24 hours and up +25.09% over the past month.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$3.60
Open:
$3.58
24h Volume:
168.08K
Relative Volume:
1.70
Market Cap:
$88.90M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-8.5641
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
+21.01%
1M Performance:
+25.09%
6M Performance:
+17.19%
1Y Performance:
+22.79%
1-Day Range:
$3.30
$3.59
1-Week Range:
$3.20
$3.615
52-Week Range:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.34 | 88.90M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Bank of America Corp DE Sells 6,891 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
3 Promising Penny Stocks With Market Caps Over $100M - simplywall.st
Anixa Biosciences’ (ANIX) Buy Rating Reaffirmed at D. Boral Capital - Defense World
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Anixa Biosciences' Breast Cancer Vaccine Receives National News Coverage | ANIX Stock News - GuruFocus
Anixa Biosciences (ANIX) Maintains 'Buy' Rating with $10 Price T - GuruFocus
Anixa Biosciences (ANIX) Maintains 'Buy' Rating with $10 Price Target | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Prevention Vaccine Gets Major Media Spotlight: How It Could Eradicate Cancer - Stock Titan
Anixa Biosciences (ANIX) to Present at ESMO Gynaecological Cance - GuruFocus
Anixa Biosciences Announces Poster Presentation on Ovarian Cance - GuruFocus
Anixa Biosciences Announces Poster Presentation On Ovarian Cancer CAR-T Clinical Trial At ESMO Gynaecological Cancers Congress 2025 - marketscreener.com
Breakthrough CAR-T Therapy for Ovarian Cancer: Anixa's Phase 1 Trial Results Coming at ESMO 2025 - Stock Titan
Jane Street Group LLC Purchases New Shares in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences (NASDAQ:ANIX) Upgraded by Wall Street Zen to Hold Rating - Defense World
All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy - MSN
Kalkine Lists top companies in the nasdaq Featuring Innovative Biotech Like Anixa Biosciences - Kalkine Media
FY2025 EPS Forecast for Anixa Biosciences Boosted by Analyst - Defense World
CEO Amit Kumar Increases Stake in Anixa Biosciences Inc with Rec - GuruFocus
Anixa Biosciences CEO Amit Kumar acquires $28,500 in stock - Investing.com Australia
Anixa Biosciences CEO Amit Kumar acquires $28,500 in stock By Investing.com - Investing.com Canada
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? - Yahoo Finance
H.C. Wainwright maintains Buy rating on Anixa Biosciences stock By Investing.com - Investing.com UK
Northern Trust Corp Trims Stock Position in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview - GuruFocus
Anixa Biosciences' Breast Cancer Vaccine Featured in NewsNation Interview | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Prevention Vaccine Hits Major Milestone: Phase 1 Trial Fully Enrolled - Stock Titan
Anixa Biosciences (ANIX) Concludes Enrollment for Breast Cancer Vaccine Trial | ANIX Stock News - GuruFocus
Anixa Biosciences Announces Completion Of Enrollment In Phase 1 Trial Of Breast Cancer Vaccine - marketscreener.com
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine - GuruFocus
Anixa Biosciences Announces Completion of Enrollment in Phase 1 Trial of Breast Cancer Vaccine | ANIX Stock News - GuruFocus
Revolutionary Breast Cancer Vaccine Achieves Major Milestone: 70% of Patients Show Promising Immune Response - Stock Titan
ANIXA BIOSCIENCES Earnings Preview: Recent $ANIX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Anixa Biosciences to Present at the iAccess Alpha Virtual Best Ideas Winter Conference 2024 on December 10 - marketscreener.com
Anixa Biosciences’ (ANIX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Tar - GuruFocus
Anixa Biosciences (ANIX) Retains 'Buy' Rating with $10 Price Target | ANIX Stock News - GuruFocus
Anixa Biosciences Inc SEC 10-Q Report - TradingView
Anixa Biosciences (ANIX) Expected to Announce Earnings on Tuesday - Defense World
Anixa Biosciences CEO Provides Letter to Shareholders Outlining - GuruFocus
Anixa Biosciences CEO Provides Letter to Shareholders Outlining Significant Progress and Advancement Towards Potentially Transformative Milestones - Nasdaq
Breakthrough: Anixa's Cancer Vaccine Shows 70% Response Rate While CAR-T Therapy Extends Patient Survival - Stock Titan
Anixa Biosciences Announces Poster Presentation on Ovarian Cancer CAR-T Clinical Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting - Stock Titan
Renaissance Technologies LLC Has $34,000 Stock Holdings in Anixa Biosciences, Inc. (NASDAQ:ANIX) - Defense World
ANIXAnixa Biosciences Inc Latest Stock News & Market Updates - Stock Titan
Anixa Biosciences, Inc. (NASDAQ:ANIX) Shares Acquired by LPL Financial LLC - Defense World
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual B - GuruFocus
Anixa Biosciences to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20th - Nasdaq
ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up - MSN
Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Presented at the Rivkin Center & American Association of Cancer Research (AACR) 14th Biennial Ovarian Cancer Research Symposium - Seeking Alpha
Anixa Biosciences (ANIX) Secures Patent to Advance CAR-T Cancer Therapy | ANIX Stock News - GuruFocus
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
| Titterton Lewis H jr | Director |
Jan 21 '25 |
Buy |
2.59 |
6,000 |
15,540 |
928,334 |
| Titterton Lewis H jr | Director |
Jan 17 '25 |
Buy |
2.57 |
10,000 |
25,700 |
922,334 |
| KUMAR AMIT | Chief Executive Officer |
Jan 15 '25 |
Buy |
2.23 |
43,000 |
95,890 |
559,925 |
| Catelani Michael | President, COO, & CFO |
Jan 15 '25 |
Buy |
2.15 |
9,289 |
19,971 |
44,500 |
| Titterton Lewis H jr | Director |
Oct 22 '24 |
Option Exercise |
2.58 |
16,000 |
41,200 |
912,334 |
| Titterton Lewis H jr | Director |
Jul 30 '24 |
Buy |
3.06 |
21,646 |
66,237 |
890,754 |
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):